It is a support menu from here.
Main Menu
Product Information
Hokunalin® Tape (tulobuterol patch), the world’s first long-acting transdermal bronchodilator, will include printing of "HOKUNALIN" on the tape surface
5.23.2006
Nitto Denko Corporation (Head Office: Osaka, President Masamichi Takemoto) and Abbott Japan Co., Ltd. (Head office of the Pharmaceutical Products Group in Osaka, President Zahir Lavji), and Maruho Co., Ltd., (Head Office: Osaka, President Koichi Takagi) have announced that Hokunalin® Tape (generic name: tulobuterol), a prolonged action b2 agonist preparation for the treatment of bronchial asthma and chronic obstructive pulmonary disease (COPD) co-developed by Abbott Japan and Nitto Denko and co-marketed by Abbott Japan and Maruho, will include printing of "HOKUNALIN" on the tape surface (see Table).
In Japan, Hokunalin Tape is one of 30 different transdermal products, which are used in the treatment of cardiovascular, gynecological and other types of diseases. The absence of printing of the drug name on the surface of many transdermal presentations could be an issue for patients, caretakers, and medical professionals. Without printing of the drug name, medical professionals and caretakers would not be certain which types of transdermal patches have been applied to patients. This might be an issue when they need to know which types of transdermal preparations have been used and what type of disease the patients have.
In order to avoid such situations, Abbott Japan Co., Ltd., Maruho Co., Ltd., and Nitto Denko Corporation have decided to print "HOKUNALIN" on the surface of Hokunalin® Tape. Printing the drug name will help increase awareness of patients, caretakers, and medical professionals (see below) and help avoid any confusion in situations.
Benefits for patients, caretakers, and medical professionals
- Patients and caretakers can confirm the type of patch used when applying it.
- The patch and liner are easily distinguishable.
- Medical professionals will know which type of transdermal preparation is being used, even when communication with patients is difficult, e.g., in emergency care settings.
Abbott Japan Co., Ltd., Maruho Co., Ltd., and Nitto Denko Corporation hope this modification will be useful for patients using Hokunalin® Tape, as well as medical professionals, and will continue to elicit the opinions of patients and medical professionals for further improvement of its products.
How to inform patients about the addition of printing of the drug name "HOKUNALIN":
- An "information sheet" will be included with Hokunalin® Tape as informational material provided from physicians, pharmacists, and other medical professionals to patients using the drug.
- A leaflet that helps medical professionals explain this modification to patients will be provided to pharmacists, physicians, and other medical professionals.
- The figures in "How to apply Hokunalin® Tape", which are to be provided to patients by medical professionals, will be modified to reflect the modification of the tape surface.
References
- About Hokunalin® Tape
- Hokunalin® Tape is the world’s first transdermal long-acting b2 agonist preparation, was co-developed by Abbott Japan Co., Ltd. and Nitto Denko Corporation, and has been available since December 1998. Hokunalin® Tape contains tulobuterol as the active ingredient, and is effective for 24 hours. It is indicated for "treatment of signs/symptoms such as dyspnea caused by airway obstruction due to bronchial asthma, acute bronchitis, chronic bronchitis, or emphysema". In the guidelines for the treatment of chronic obstructive pulmonary disease (COPD) and bronchial asthma, Hokunalin® Tape is recommended as a long-acting bronchodilator. Hokunalin® Tape received the Science and Technology Agency Director-General's award in 1998 and the Pharmaceutical Society of Japan's Drug Discovery Research Award in 2001.
- About Nitto Denko Corporation
- Nitto Denko supplies various sophisticated products to the global market and supports a broad range of industrial activities. Based on core macromolecule synthesis and adhesion processing technologies, the company creates products, such as LCD optical films, automobile-related materials and transdermal drug delivery patches, with superior features by merging different advanced technologies, such as LCD optical films, automobile-related materials and transdermal drug delivery patches. It is headquartered in Osaka and has more than 100 groups. The companies employ about 27,000 people and provide products for the world market.
- About Abbott
- Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.
In Japan, the more than 1,900 people of Abbott are devoted to the manufacture and development of drugs and the distribution and marketing of pharmaceutical and medical products, nutritional products, medical devices/instruments, and diagnostics. Abbott’s main offices in Japan are located in Tokyo, Osaka, Fukui, and Chiba. - About Maruho Co., Ltd.
- Maruho is a mid-sized medical ethical drug company devoted to research, development, manufacturing, and marketing of ethical drugs, whose motto is to "provide high-quality contribution to human health". Its main offices are located in Osaka. The company employs more than 800 people, and has a sales force that covers all of Japan. Its R&D laboratory is located in Kyoto, and its production center in Hikone.
Contuct Us
Footer Area
